Transcriptomic analysis identifies CYP27A1 as a diagnostic marker for the prognosis and immunity in lung adenocarcinoma

BMC Immunology

Research

Yi Yin¹  Yunjian Huang¹  Muqun He¹  Xianhe Xie² 

[1] Department of Medical Oncology, Clinical Oncology School of, Fujian Medical University, Fujian Cancer Hospital, 350014, Fuzhou, China;Department of Oncology, Molecular Oncology Research Institute, Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital of Fujian Medical University, 350005, Fuzhou, China;

关键词: Immune infiltrates;    TCGA;    Lipid metabolism;    Lung cancer;    Prognosis;   

DOI  :  10.1186/s12865-023-00572-1

 received in 2023-07-10, accepted in 2023-09-14,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe association between lipid metabolism disorder and carcinogenesis is well-established, but there is limited research on the connection between lipid metabolism-related genes (LRGs) and lung adenocarcinoma (LUAD). The objective of our research was to identify LRGs as the potential biomarkers for prognosis and assess their impact on immune cell infiltration in LUAD.MethodsWe identified novel prognostic LRGs for LUAD patients via the bioinformatics analysis. CYP27A1 expression level was systematically evaluated via various databases, such as TCGA, UALCAN, and TIMER. Subsequently, LinkedOmics was utilized to perform the CYP27A1 co-expression network and GSEA. ssGSEA was conducted to assess the association between infiltration of immune cells and CYP27A1 expression. CYP27A1’s expression level was validated by qRT-PCR analysis.ResultsCYP27A1 expression was decreased in LUAD. Reduced CYP27A1 expression was linked to unfavorable prognosis in LUAD. Univariate and multivariate analyses indicated that CYP27A1 was an independent prognostic biomarker for LUAD patients. GSEA results revealed a positive correlation between CYP27A1 expression and immune-related pathways. Furthermore, CYP27A1 expression was positively correlated with the infiltration levels of most immune cells.ConclusionCYP27A1 is a potential biomarker for LUAD patients, and our findings provided a novel perspective to develop the prognostic marker for LUAD patients.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 2

Fig. 4

Fig. 1

Fig. 3

Fig. 4

Fig. 4